NeoGenomics

About

NeoGenomics is a cancer reference laboratory that provides cancer testing and partnership programs to pathologists and oncologists.

Fort Myers,Florida,United States
501 - 1000
http://www.neogenomics.com

Highlights

Details

Last Funding Type: Post-IPO Equity
Last Funding Money Raised: $200M
Industries: Biotechnology,Genetics,Health Care,Health Diagnostics,Medical,Pharmaceutical
Founded date: Oct 29, 1998
Number Of Employee: 501 - 1000
Operating Status: Active
Stock Symbol: nasdaq:NEO
Legal Name: NeoGenomics Laboratories, Inc.

NeoGenomics is a cancer reference laboratory that provides cancer testing and partnership programs to pathologists and oncologists. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

4

$385.10M

NeoGenomics has raised a total of $385.10M in funding over 2 rounds. Their latest funding was raised on May 5, 2021 from a Post-IPO Equity round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
May 5, 2021	Post-IPO Equity	$200M	13	—	—	Detail
Dec 22, 2016	Post-IPO Debt	$150M	—	—	—	Detail
Mar 30, 2009	Post-IPO Equity	$500K	—	—	—	Detail
Nov 12, 1999	IPO	$34.60M	—	—	—	Detail

Investments

Number of Investments

Number of Lead Investments

3

1

NeoGenomics has made 3 investments. Their most recent investment was on Oct 14, 2022, when Fulcrum raised $18.80M.

Date Company Name	Round	Money Raised	Industry	Lead Investor
Oct 14, 2022 Fulcrum	Series A	$18.80M	Enterprise Resource Planning (ERP)	—
Dec 9, 2020 Squire	Series C	$45M	Consumer	—
May 26, 2020 Inivata	Corporate Round	$25M	Biotechnology	Yes

Investors

Number of Lead Investors

Number of Investors

—

13

NeoGenomics is funded by 13 investors. Avidity Partners and Blue Water Life Science Fund are the most recent investors.

Investor Name	Lead Investor	Funding Round
Avidity Partners	—	Post-IPO Equity
Blue Water Life Science Fund	—	Post-IPO Equity
Casdin Capital	—	Post-IPO Equity
Driehaus Capital Management	—	Post-IPO Equity
Farallon Capital Management	—	Post-IPO Equity
Federated Kaufmann Fund	—	Post-IPO Equity
First Light Asset Management	—	Post-IPO Equity
Janus Henderson Investors	—	Post-IPO Equity
Pura Vida Investments	—	Post-IPO Equity
RS Investments	—	Post-IPO Equity

Employee Profiles

Number of Employee Profiles

17

NeoGenomics has 17 current employee profiles, including Executive George A. Cardoza

Executive

Executive

Executive

Executive

Executive

Exits

NeoGenomics has had 1 exits. NeoGenomics most notable exits include Inivata

Date	Company Name	Exit Type	Industry
May 5, 2021	Inivata	M&A	Biotechnology	Detail

Acquisition

NeoGenomics has acquired 5 organizations. Their most recent acquisition was Path Logic on Jul 8, 2014. They acquired Path Logic for $6M.

Date Company Name	Industry	Acquisition Type	Price
Jul 8, 2014 Path Logic	Biotechnology	acquisition	$ 6M	Detail
Oct 21, 2015 Clarient	Biotechnology	acquisition	—	Detail
Oct 23, 2018 Genoptix	Communities	acquisition	—	Detail
Mar 24, 2021 Trapelo Health	Health Care	acquisition	$ 65M	Detail
May 5, 2021 Inivata	Biotechnology	acquisition	—	Detail